These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 33374949)

  • 21. Suppression of SREBP-1 Expression by Simvastatin Decreases Visfatin-Induced Chemoresistance to Sunitinib in Human Renal Carcinoma 786-O Cells.
    Chen TC; Huang CW; Lo CY; Chen CN; Chang SF; Chen YY
    Life (Basel); 2022 Nov; 12(11):. PubMed ID: 36431025
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Wogonin Induces Apoptosis and Reverses Sunitinib Resistance of Renal Cell Carcinoma Cells
    Wang Y; Chen S; Sun S; Liu G; Chen L; Xia Y; Cui J; Wang W; Jiang X; Zhang L; Zhu Y; Zou Y; Shi B
    Front Pharmacol; 2020; 11():1152. PubMed ID: 32792963
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A five-gene signature may predict sunitinib sensitivity and serve as prognostic biomarkers for renal cell carcinoma.
    Chen YL; Ge GJ; Qi C; Wang H; Wang HL; Li LY; Li GH; Xia LQ
    J Cell Physiol; 2018 Oct; 233(10):6649-6660. PubMed ID: 29327492
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PTEN Is Involved in Sunitinib and Sorafenib Resistance in Renal Cell Carcinoma.
    Sekino Y; Hagura T; Han X; Babasaki T; Goto K; Inoue S; Hayashi T; Teishima J; Shigeta M; Taniyama D; Kuraoka K; Sentani K; Yasui W; Matsubara A
    Anticancer Res; 2020 Apr; 40(4):1943-1951. PubMed ID: 32234883
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fibroblast Growth Factor Receptor-Dependent and -Independent Paracrine Signaling by Sunitinib-Resistant Renal Cell Carcinoma.
    Tran TA; Leong HS; Pavia-Jimenez A; Fedyshyn S; Yang J; Kucejova B; Sivanand S; Spence P; Xie XJ; Peña-Llopis S; Power N; Brugarolas J
    Mol Cell Biol; 2016 Jul; 36(13):1836-55. PubMed ID: 27141054
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterisation of the Morphological, Functional and Molecular Changes in Sunitinib-Resistant Renal Cell Carcinoma Cells.
    Kamli H; Glenda GC; Li L; Vesey DA; Morais C
    J Kidney Cancer VHL; 2018; 5(3):1-9. PubMed ID: 30109169
    [TBL] [Abstract][Full Text] [Related]  

  • 27. p21-activated kinase 1 determines stem-like phenotype and sunitinib resistance via NF-κB/IL-6 activation in renal cell carcinoma.
    Zhu Y; Liu H; Xu L; An H; Liu W; Liu Y; Lin Z; Xu J
    Cell Death Dis; 2015 Feb; 6(2):e1637. PubMed ID: 25675297
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The microRNA signature of patients with sunitinib failure: regulation of UHRF1 pathways by microRNA-101 in renal cell carcinoma.
    Goto Y; Kurozumi A; Nohata N; Kojima S; Matsushita R; Yoshino H; Yamazaki K; Ishida Y; Ichikawa T; Naya Y; Seki N
    Oncotarget; 2016 Sep; 7(37):59070-59086. PubMed ID: 27487138
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells.
    Sato H; Siddig S; Uzu M; Suzuki S; Nomura Y; Kashiba T; Gushimiyagi K; Sekine Y; Uehara T; Arano Y; Yamaura K; Ueno K
    Eur J Pharmacol; 2015 Jan; 746():258-66. PubMed ID: 25455500
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of mutations associated with acquired resistance to sunitinib in renal cell cancer.
    Elgendy M; Fusco JP; Segura V; Lozano MD; Minucci S; Echeveste JI; Gurpide A; Andueza M; Melero I; Sanmamed MF; Ruiz MR; Calvo A; Pascual JI; Velis JM; Miñana B; Valle RD; Pio R; Agorreta J; Abengozar M; Colecchia M; Brich S; Renne SL; Guruceaga E; Patiño-García A; Perez-Gracia JL
    Int J Cancer; 2019 Oct; 145(7):1991-2001. PubMed ID: 30848481
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.
    Serova M; de Gramont A; Tijeras-Raballand A; Dos Santos C; Riveiro ME; Slimane K; Faivre S; Raymond E
    Cancer Chemother Pharmacol; 2013 May; 71(5):1297-307. PubMed ID: 23479136
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma.
    Motzer RJ; Escudier B; Gannon A; Figlin RA
    Oncologist; 2017 Jan; 22(1):41-52. PubMed ID: 27807302
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cellular Adaptation to VEGF-Targeted Antiangiogenic Therapy Induces Evasive Resistance by Overproduction of Alternative Endothelial Cell Growth Factors in Renal Cell Carcinoma.
    Han KS; Raven PA; Frees S; Gust K; Fazli L; Ettinger S; Hong SJ; Kollmannsberger C; Gleave ME; So AI
    Neoplasia; 2015 Nov; 17(11):805-16. PubMed ID: 26678908
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interleukin-6 induces drug resistance in renal cell carcinoma.
    Ishibashi K; Koguchi T; Matsuoka K; Onagi A; Tanji R; Takinami-Honda R; Hoshi S; Onoda M; Kurimura Y; Hata J; Sato Y; Kataoka M; Ogawsa S; Haga N; Kojima Y
    Fukushima J Med Sci; 2018 Dec; 64(3):103-110. PubMed ID: 30369518
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma.
    Shibasaki N; Yamasaki T; Kanno T; Arakaki R; Sakamoto H; Utsunomiya N; Inoue T; Tsuruyama T; Nakamura E; Ogawa O; Kamba T
    PLoS One; 2015; 10(6):e0130980. PubMed ID: 26114873
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Commentary on "Cytoreductive radiofrequency ablation in patients with metastatic renal cell carcinoma (RCC) with small primary tumours treated with sunitinib or interferon-α." Tsimafeyeu I, Zart JS, Chung B, Kidney Cancer Research Bureau, Moscow, Russian Federation.: BJU Int 2013; 112(1):32-8. [Epub 2013 Jun 7]. doi: 10.1111/bju.12107.
    Boorjian S
    Urol Oncol; 2014 May; 32(4):514-5. PubMed ID: 24767689
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Decreased apoptosis repressor with caspase recruitment domain confers resistance to sunitinib in renal cell carcinoma through alternate angiogenesis pathways.
    Gobe GC; Ng KL; Small DM; Vesey DA; Johnson DW; Samaratunga H; Oliver K; Wood S; Barclay JL; Rajandram R; Li L; Morais C
    Biochem Biophys Res Commun; 2016 Apr; 473(1):47-53. PubMed ID: 26995091
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metabolomic profile of glycolysis and the pentose phosphate pathway identifies the central role of glucose-6-phosphate dehydrogenase in clear cell-renal cell carcinoma.
    Lucarelli G; Galleggiante V; Rutigliano M; Sanguedolce F; Cagiano S; Bufo P; Lastilla G; Maiorano E; Ribatti D; Giglio A; Serino G; Vavallo A; Bettocchi C; Selvaggi FP; Battaglia M; Ditonno P
    Oncotarget; 2015 May; 6(15):13371-86. PubMed ID: 25945836
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cytoreductive radiofrequency ablation in patients with metastatic renal cell carcinoma (RCC) with small primary tumours treated with sunitinib or interferon-α.
    Tsimafeyeu I; Zart JS; Chung B
    BJU Int; 2013 Jul; 112(1):32-8. PubMed ID: 23746142
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of the breast cancer resistance protein (BCRP/ABCG2) in clear cell renal cell carcinoma.
    Reustle A; Fisel P; Renner O; Büttner F; Winter S; Rausch S; Kruck S; Nies AT; Hennenlotter J; Scharpf M; Fend F; Stenzl A; Bedke J; Schwab M; Schaeffeler E
    Int J Cancer; 2018 Dec; 143(12):3181-3193. PubMed ID: 30070687
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.